February 5, 2014 / 1:05 PM / 4 years ago

BRIEF-GlaxoSmithKline CEO plays down generic Advair threat

Feb 5 (Reuters) - GlaxoSmithKline Plc CEO Andrew Witty told reporters: * CEO says European respiratory business remains extremely strong despite

“patchy” generics * CEO says new generics to Advair not substitutable in many European markets * CEO says U.S. Advair generics “some distance in the future” * CEO says pleased with Breo start * CEO says nine potential respiratory launches coming through * CEO says long-term trend in emerging markets still upwards, despite

volatility; view remains undimmed * CEO says darapladib and mage-3 drugs remain “intriguing” opportunities * CEO says will file malaria vaccine

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below